76 results about "Fab Fragments" patented technology

The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways.

The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes.

Antigen-binding proteins specific for HLA-A2-restricted Wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv (scFv) fragments, as well as chimeric antigen receptors. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the antigen-binding proteins are provided. Methods of using the antigen-binding proteins in the treatment of hyperproliferative diseases such as cancer are also disclosed.

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

The present invention relates to an anticancer drug, an energized fusion protein Anti-CD20(Fab)-LDM of lidamycin, a gene encoding the same; and further relates to a method for construction of the energized fusion protein in a genetic engineering manner and the use of the energized fusion protein. The applicant provides an anti-tumor drug with a good targeting ability by providing the energized fusion protein.

Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.

Human antibody fragments (Fab 14.6.19 and Fab 14.6.20) including polynucleotides and amino acids (SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6) that identify them. Both Fabs are fully human, are affinity matured in vivo, are highly specific for breast cancer, and target an antigen that is immumogenic in vivo. Thus, each Fab may be a useful clinical reagent for diagnosis or therapy of breast cancer and may also lead to the discovery of a novel immunogenic and tumor specific breast cancer antigen.

The inventions provides methods and kits for the dissociation of Fcγ-receptor-IgG complexes, and methods and kits for the isolation of IgG and Fc and Fab fragments of IgG.

The invention provides a preparation method for rheumatoid factor detection reagent. The method comprises the following steps of: coupling IgG molecules and latex particles to obtain IgG sensitizing latex; digesting and decomposing obtained IgG sensitizing latex by enzyme to obtain mixture of Fab fragment and Fc fragment sensitizing latex; separating and purifying the Fab fragment and Fc fragmentsensitizing latex to obtain the Fc fragment sensitizing latex; causing the Fc fragment on the sensitizing latex to be denatured, and obtaining the denatured Fc fragment sensitizing latex which is prepared into rheumatoid factor detection reagent. The method not only can produce rheumatoid factor detection reagent with high specificity, but also has low production cost, simple technique and is convenient to large-scale industrialization production.

The invention relates to a human CD19 and CD3 binding bispecific antibody. The human CD19 and CD3 binding bispecific antibody comprises Fab fragments for specifically recognizing cell membrane antigens and single-chain antibodies for recognizing CD3 molecules. The single-chain antibodies for recognizing the CD3 molecules are connected with C tail ends of CH1 region peptide fragments of the Fab fragments by hydrophilic connecting peptides-linker; the Fab fragments for specifically recognizing the cell membrane antigens are of Fab structures with specific human CD19 recognizing antigens, the structure of the human CD19 and CD3 binding bispecific antibody is shown, and the connecting peptides-linker comprises 8-20 hydrophilic amino acid.

The present invention relates to tetravalent bispecific antibodies (TetBiAbs), methods of making and methods of using the same for diagnostics and for the treatment of cancer or immune disorders. TetBiAbs feature a second pair of Fab fragments with a second antigen specificity attached to the C-terminus of an antibody, thus providing a molecule that is bivalent for each of the two antigen specificities. The tetravalent antibody is produced by genetic engineering methods, by linking an antibody heavy chain covalently to a Fab light chain, which associates with its cognate, co-expressed Fab heavy chain.

Antibody Fab fragments specific for the EGF receptor are disclosed, as are compositions and kits comprising these Fab proteins. The Fab proteins may be conjugated to drugs or other therapeutic agents or to diagnostic agents. Also disclosed are methods for diagnosing and treating diseases such as tumors and cancer in which cells express high levels of the EGFR, using the foregoing Fab molecules and conjugates.

Improved expression of active antibody fragments (Fabs) is achieved by truncating a heavy chain constant region. Truncation of the C_H1 domain of a Fab fragment can increase yield of soluble active antibody fragment in Pseudomonas fluorescens. Another embodiment of the invention includes secretion of the light chain and a fragment of the heavy chain with various C-termini (e.g., V_H-C_H1 truncated to different lengths). The truncated C_H1 region can be used as a scaffold to create other Fabs. Also included is truncation of the kappa light chain and/or lambda light chain domains of a Fab fragment. The invention also includes expression of Fab fragments fused to other peptides or molecules (e.g., toxins, proteins, peptides, enzymes, etc.).

The invention belongs to the technical field of biochemistry, and particularly relates to an antigen detection kit, a preparation method for the antigen detection kit, and an antigen detection method.The antigen detection kit comprises an R1 solution and an R2 solution, wherein the R1 solution comprises a monoclonal antibody containing Fab fragments and Fc fragments, and a biotin-marked monoclonal antibody only containing Fab fragments or a biotin-marked monoclonal antibody that is not homologous to the monoclonal antibody containing the Fab fragments and the Fc fragments; and the R2 solutioncomprises streptavidin magnetic beads, and a secondary antibody marked by a chemiluminescent marker. The antigen detection kit provided by the embodiment of the invention has the advantages that structures of the two monoclonal antibodies in the R1 solution are both undamaged, and magnetic microspheres are dispensed with, so that good antigen and antibody binding effects can be ensured, and the antigen content can be accurately measured with assistance of the R2 solution.